Literature DB >> 30178541

Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer.

Xue-Feng Ni1, Jun Wu1, Mei Ji1, Ying-Jie Shao2, Bin Xu3,4, Jing-Ting Jiang3,4, Chang-Ping Wu1.   

Abstract

AIM: Systemic inflammatory response is closely related to tumor progression. We retrospectively investigated relationships between systemic inflammatory scores, C-reactive protein/albumin (CRP/Alb) ratio (CAR) and clinical characteristics in advanced non-small-cell lung cancer (NSCLC) in 436 patients to find better clinical predictors of NSCLC prognosis.
METHODS: Blood specimens were collected 1 week before treatment to test for systemic inflammatory scores and albumin. Patients' overall survival (OS) was calculated via Kaplan-Meier method. Single-factor log-rank and multivariate Cox regression analyses and receiver operating characteristic curves were used to evaluate the prognostic significance of CAR and other systemic inflammatory indexes in predicting OS.
RESULTS: Kaplan-Meier method showed that Glasgow prognosis score (GPS), modified GPS (mGPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and monocyte/lymphocyte ratio (MLR) were reliable prognostic factors for advanced NSCLC. CAR was positively correlated with GPS, mGPS, NLR, PLR and MLR in these patients. CAR was an independent risk factor for OS in advanced NSCLC, and was more closely associated with prognosis than were GPS, mGPS, NLR, PLR or MLR.
CONCLUSION: In advanced NSCLC patients, CAR may be a better predictor of prognosis compared with other inflammatory markers. A prospective multicenter study is needed to verify these findings.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  advanced stage, CRP/Alb ratio, non-small cell lung cancer; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30178541     DOI: 10.1111/ajco.13055

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  14 in total

1.  Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.

Authors:  Tatsuki Ikoma; Mototsugu Shimokawa; Toshihiko Matsumoto; Shogen Boku; Tomoyo Yasuda; Nobuhiro Shibata; Yusuke Kurioka; Masahiro Takatani; Tetsuji Nobuhisa; Tsutomu Namikawa; Hiroyuki Kitagawa; Kazuhiro Hanazaki; Keitaro Doi; Takanobu Shimada; Takehiko Tsumura; Hiroyuki Marusawa; Seichiro Kanaya; Shuko Morita; Tetsurou Inokuma; Hiroki Nagai; Hisateru Yasui; Hironaga Satake
Journal:  Cancer Immunol Immunother       Date:  2022-08-04       Impact factor: 6.630

2.  Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods.

Authors:  Jian-Guo Zhou; Ada Hang-Heng Wong; Haitao Wang; Fangya Tan; Xiaofei Chen; Su-Han Jin; Si-Si He; Gang Shen; Yun-Jia Wang; Benjamin Frey; Rainer Fietkau; Markus Hecht; Hu Ma; Udo S Gaipl
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

3.  Nomograms based on lactate dehydrogenase to albumin ratio for predicting survival in colorectal cancer.

Authors:  Yugang Hu; Yanxiang Zhou; Yinghao Cao; Hao Wang; Yuanting Yang; Riyue Jiang; Qincheng Gong; Qing Zhou
Journal:  Int J Med Sci       Date:  2022-05-29       Impact factor: 3.642

4.  The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303.

Authors:  Takuro Miyazaki; Hisashi Saji; Hiroshige Nakamura; Takeshi Nagayasu; Norihito Okumura; Masanori Tsuchida; Makoto Sonobe; Keiju Aokage; Masayuki Nakao; Tomohiro Haruki; Morihito Okada; Kenji Suzuki; Masayuki Chida; Ichiro Yoshino
Journal:  Surg Today       Date:  2022-02-24       Impact factor: 2.540

5.  Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.

Authors:  Taizo Uchimoto; Kazumasa Komura; Yuya Fujiwara; Kenkichi Saito; Naoki Tanda; Tomohisa Matsunaga; Atsushi Ichihashi; Takeshi Tsutsumi; Takuya Tsujino; Yuki Yoshikawa; Yudai Nishimoto; Tomoaki Takai; Koichiro Minami; Kohei Taniguchi; Tomohito Tanaka; Hirofumi Uehara; Hajime Hirano; Hayahito Nomi; Naokazu Ibuki; Kiyoshi Takahara; Teruo Inamoto; Haruhito Azuma
Journal:  Med Oncol       Date:  2019-11-21       Impact factor: 3.064

6.  The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer.

Authors:  Zhiyao Fan; Kun Fan; Yitao Gong; Qiuyi Huang; Chao Yang; He Cheng; Kaizhou Jin; Quanxing Ni; Xianjun Yu; Guopei Luo; Chen Liu
Journal:  Cancer Manag Res       Date:  2019-09-30       Impact factor: 3.989

Review 7.  Prognostic Value of C-Reactive Protein-to-Albumin Ratio in Head and Neck Cancer: A Meta-Analysis.

Authors:  Chih-Wei Luan; Hsin-Yi Yang; Yao-Te Tsai; Meng-Chiao Hsieh; Hsin-Hsu Chou; Kuo-Su Chen
Journal:  Diagnostics (Basel)       Date:  2021-02-26

8.  Is C-Reactive Protein/Albumin Ratio of Advanced-Stage Non-small Cell Lung Cancer Patients Able to Predict Mortality in the Admission for Palliative Care?

Authors:  Irfan Karahan; Selim Yalçin
Journal:  Indian J Palliat Care       Date:  2020-08-29

9.  Preoperative Serum Hypersensitive-c-Reactive-Protein (Hs-CRP) to Albumin Ratio Predicts Survival in Patients with Luminal B Subtype Breast Cancer.

Authors:  Xiujun Liu; Xiuchun Guo; Zhiqiang Zhang
Journal:  Onco Targets Ther       Date:  2021-07-09       Impact factor: 4.147

10.  The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis.

Authors:  Xinhua Cui; Zhiqiang Jia; Dingchao Chen; Chunwei Xu; Peng Yang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.